Imugene (ASX:IMU) is an immuno-oncology focused biopharmaceutical company developing HER-2+ gastric and breast cancer immunotherapies. Our mission is to build a pipeline of B-cell peptide cancer vaccines.
A sophisticated investor is defined under Section 708 of the Corporations Act (net assets of $2.5 million or annual incomes in excess of $250,000).
They are eligible to receive information regarding wholesale investment opportunities that are not available to regular or retail investors.
Please subscribe if you would like to be alerted to these types of opportunities.